Description
Ofloxacin, a second-generation fluoroquinolone, was once widely prescribed for mild-to-moderate urinary and respiratory tract infections. A semisynthetic antibiotic, it is a racemic mixture, with its l-enantiomer—levofloxacin—remaining in common clinical use. Active against a broad spectrum of aerobic gram-positive and gram-negative bacteria, ofloxacin works by inhibiting DNA gyrase and topoisomerase IV, enzymes essential for bacterial transcription and replication. This paper offers a comprehensive review of its therapeutic role and clinical relevance.